{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:21:23Z","timestamp":1793816483427,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1053\/j.ajkd.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T20:55:46Z","timestamp":1643057746000},"page":"164-173.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study"],"prefix":"10.1053","volume":"80","author":[{"given":"Silvia J.","family":"Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rigatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Komenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Sucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Bota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Tuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9069","key":"10.1053\/j.ajkd.2022.01.002_bib1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"9176","key":"10.1053\/j.ajkd.2022.01.002_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ace-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2022.01.002_bib3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IGA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2022.01.002_bib4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2022.01.002_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"15 suppl","key":"10.1053\/j.ajkd.2022.01.002_bib7","first-page":"s307","article-title":"The burden of hyperkalemia in patients with cardiovascular and renal disease","volume":"21","author":"Dunn","year":"2015","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1053\/j.ajkd.2022.01.002_bib8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.amjmed.2015.05.040","article-title":"Management of hyperkalemia: an update for the internist","volume":"128","author":"Kovesdy","year":"2015","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2022.01.002_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","article-title":"Metabolic complications in elderly adults with chronic kidney disease","volume":"60","author":"Drawz","year":"2012","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"22","key":"10.1053\/j.ajkd.2022.01.002_bib10","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/jama.2015.9230","volume":"314","author":"Palmer","year":"2015","journal-title":"Hyperkalemia. JAMA."},{"issue":"3","key":"10.1053\/j.ajkd.2022.01.002_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2022.01.002_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.mayocp.2016.01.012","article-title":"Achieving the benefits of a high-potassium, paleolithic diet, without the toxicity","volume":"91","author":"Palmer","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1053\/j.ajkd.2022.01.002_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2022.01.002_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jamia\/ocx078","article-title":"Assessing the quality of administrative data for research: a framework from the Manitoba Centre for Health Policy","volume":"25","author":"Smith","year":"2017","journal-title":"J\u00a0Am Med Inform Assoc"},{"issue":"8","key":"10.1053\/j.ajkd.2022.01.002_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2022.01.002_bib16","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ijrobp.2011.10.025","article-title":"Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy","volume":"83","author":"Park","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"26","key":"10.1053\/j.ajkd.2022.01.002_bib17","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1002\/sim.7019","article-title":"Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study","volume":"35","author":"Mi","year":"2016","journal-title":"Stat Med"},{"issue":"17","key":"10.1053\/j.ajkd.2022.01.002_bib18","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/eurheartj\/ehn346","article-title":"Discontinuation of statin therapy following an acute myocardial infarction: a population-based study","volume":"29","author":"Daskalopoulou","year":"2008","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1053\/j.ajkd.2022.01.002_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.jhh.1001873","article-title":"Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study","volume":"19","author":"Bourgault","year":"2005","journal-title":"J\u00a0Hum Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2022.01.002_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin c","volume":"367","author":"Inker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2022.01.002_bib21","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the Asian-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Global Health"},{"issue":"11 suppl","key":"10.1053\/j.ajkd.2022.01.002_bib22","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"issue":"11 suppl","key":"10.1053\/j.ajkd.2022.01.002_bib23","first-page":"S311","article-title":"Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors","volume":"22","author":"Epstein","year":"2016","journal-title":"Am J Manag Care"},{"issue":"9","key":"10.1053\/j.ajkd.2022.01.002_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: s safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"issue":"1","key":"10.1053\/j.ajkd.2022.01.002_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2022.01.002_bib26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"20","key":"10.1053\/j.ajkd.2022.01.002_bib27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2022.01.002_bib28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting\u2013enzyme inhibitor benazepril on the progression of chronic renal insufficiency.","volume":"334","author":"Maschio","year":"1996","journal-title":"New Engl\u00a0J\u00a0Med."},{"issue":"2","key":"10.1053\/j.ajkd.2022.01.002_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2022.01.002_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the Amethyst-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"21","key":"10.1053\/j.ajkd.2022.01.002_bib31","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the Harmonize randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2022.01.002_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:42:44Z","timestamp":1759462964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0272638622000348"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.01.002","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}